Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study

Table 2

Patient details with chemotherapy regimens and efficacy evaluation.

No.	Age	Sex	If others, please specify	Cancer stage	Setting in which NDLS was used	NDLS chemotherapy used	Overall response as per the RECIST (1.1)
1	48	Male	High-grade pleomorphic sarcoma of mandible	III	Neoadjuvant setting	NDLS plus gemcitabine	CR
2	42	Male	Leiomyosarcoma	II	Adjuvant setting	NDLS plus gemcitabine	Not applicable
3	35	Male	Leiomyosarcoma	II	Adjuvant setting	NDLS plus gemcitabine	Not applicable
4	55	Female	Leiomyosarcoma	II	Adjuvant setting	NDLS plus gemcitabine	Not applicable
5	49	Female	Leiomyosarcoma	IV	Metastatic setting	NDLS plus gemcitabine	NE
6	44	Female	Leiomyosarcoma	IV	Metastatic setting	NDLS plus gemcitabine	SD
7	46	Female	Leiomyosarcoma	IV	Metastatic setting	NDLS plus gemcitabine	CR
8	58	Female	Leiomyosarcoma	IV	Metastatic setting	NDLS plus gemcitabine	PR
9	59	Male	Malignant fibrous histiocytoma of right thigh	IV	Metastatic setting	NDLS plus gemcitabine	PR
10	52	Female	Extraskeletal myxoid chondrosarcoma	IV	Metastatic setting	NDLS plus cyclophosphamide	PD
11	19	Female	Osteosarcoma of left femur	IV	Metastatic setting	NDLS plus gemcitabine	PD

Note. Efficacy response was not evaluated for patients in adjuvant setting. Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NDLS, nanosomal docetaxel lipid suspension; NE, not evaluated.